NCT01622075已完成3 期
A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent
B. Braun Medical International Trading Company Ltd.1 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2011年3月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 220
- 试验地点
- 1
- 主要终点
- Late lumen loss in segment section at M9
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of successful interventional therapy and unblocked blood vessel maintaining in the treatment of coronary in-stent restenosis by paclitaxel -eluting PTCA- balloon catheter (3μg/mm2 balloon surface area) versus paclitaxel-eluting stent Taxus® Liberte, and the reference diameter of coronary artery stenosis is 2.5mm-4.0mm and the length ≤30mm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Related to patients
- •Patients with stable angina, unstable angina, old myocardial infarction or proven asymptomatic ischemia
- •Restenosis after the first stent implant
- •Patients who can receive any kind of coronary revascularization (including balloon angioplasty, stent implantation or coronary artery bypass grafting)
- •Patient aged 18-80 (including 18 and 80)
- •Female patients of childbearing age in the study period shall not be pregnant or protocol to be pregnant, it is suggested that patients shall take sufficient contraception measures till (including) the follow-up visit of month 9
- •Patients who agree to accept the angiography follow-up visits of month 9
- •Patients who agree to accept the clinical visits at Day 30, Month 6 and Month 12
- •Patients can understand the study objectives psychologically and linguistically and show the sufficient compliance to the study protocol. Patients present acceptance of the risks and benefits described in the informed consent form.
- •Related to lesion
- •Drug-eluting stent restenosis: Type Mehran I, Type II and Type III; the reference blood vessel diameter is 2.5 mm-4.0 mm, length ≤30mm
- •Before surgery, stenosis diameter must be ≥70% or ≥50% and accompanied by ischemia
- •The distance between other lesion requires interventional therapy and the target lesion must be >10mm
- •In the stent group, up to two paclitaxel drug stents are permitted to be implanted in series
排除标准
- •Related to patients
- •Patients with myocardial infarction within one week
- •Patients with severe congestive heart failure or NYHA IV severe heart failure
- •Patients with severe valvular heart disease
- •Female patients in pregnancy or lactation
- •Patients with the life expectancy not exceeding 1 year or the factors causing difficult clinical follow-up visits
- •Patients with hemorrhagic tendency, prohibited to take anticoagulants or antiplatelet drugs
- •Patients with stroke within 6 months before the surgery
- •Patients taking part in any other clinical tests
- •Existing sever renal failure (GFR<30ml/min) or the history, so not meeting the conditions of angiography
- •Patients with cardiac transplantation
- •Patients not included for other reasons from the investigators
- •Related to lesion
- •Evidence of extensive thrombus in target blood vessel before the intervention
- •Percutaneous coronary intervention for many in-stent restenosis lesions in same artery
- •3-vessel disease that all need to be intervented
- •In bifurcation lesions, branch open blood vessel diameter ≥2.5mm
- •Percutaneous coronary intervention of venous graft
- •Entire shut of Grade TIMI 0 blood flow (Type Mehran IV stenosis)
- •Open lesion at left primary and within 2mm
- •Related to concomitant therapy
- •Patients cannot tolerate aspirin and/or clopidogrel, patients with the history of neutrocytopenia or thrombocytopenia, or patients with severe hypohepatia and prohibited to take clopidogrel
- •Patients known allergic to paclitaxel
- •Patients with the history of leucopenia (numeration of leukocytes <3x109/L, exceeding 3 days), neutrocytopenia (ANC<1000 neutrocytes/mm3, exceeding 3 days) or thrombocytopenia (<100,000 platelets/mm3
- •Patients with the history of peptic ulcer or gastrointestinal hemorrhage in the past 6 months
结局指标
主要结局
Late lumen loss in segment section at M9
时间窗: One year
To measure the diameter loss in segment restenosis of the target lesion vessel by using angiography
次要结局
- Outcomes of clinical follow-up visits for drug stent versus drug balloon(Two year)
- Success rate of the interventional therapy(Two year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)Iron Deficiency AnemiaNCT00982007American Regent, Inc.997
尚未招募
不适用
Clinical Study on the Noninvasive Lung Fluid Monitoring System in Guiding the Treatment of Heart FailureHeart FailureNCT06102031Shanghai Zhongshan Hospital1,000
终止
3 期
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-032)(TERMINATED)HIV InfectionNCT00443703Merck Sharp & Dohme LLC352
终止
3 期
MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)HIV InfectionNCT00443729Merck Sharp & Dohme LLC355
终止
4 期
Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice ForielleInfertilityNCT03387059Merck KGaA, Darmstadt, Germany9